MIAMI—BioTissue Holdings Inc. has completed its name change from TissueTech, Inc. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Following the name change, the former TissueTech, Inc. has become BioTissue Holdings Inc., and its subsidiaries BioTissue Inc. is now BioTissue Ocular Inc., and the former Amniox Medical, Inc. is now BioTissue Surgical Inc. The biotech company, based here, harnesses human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound and musculoskeletal applications.

“For over 25 years, the BioTissue name has been representative of leadership in ocular regenerative healing. Our name change allows us to showcase how our experience and expertise extends into the surgical space under the same trusted brand,” said Ted Davis, president and CEO, BioTissue. “Also, health care professionals and their patients can rest assured that we will continue to deliver the same high-quality products on which they rely.”
 
BioTissue’s innovative amniotic membrane product families Prokera, AmnioGraft, AmnioGuard, Neox and Clarix will retain their trusted brand names. All these products use the company’s proprietary CryoTek cryopreservation technology designed to retain the tissue’s structural and functional integrity.
 
BioTissue reports that nearly 700,000 patients have been treated with its products, and its scientific and clinical advancements have been documented in over 390 peer-reviewed publications. BioTissue is conducting multiple investigational new drug clinical trials to secure biologic license applications for specific indications to address unmet clinical needs in the ocular, orthopedics and wound management markets.